Judah Frommer
Stock Analyst at Morgan Stanley
(3.98)
# 594
Out of 4,981 analysts
182
Total ratings
60.9%
Success rate
7.4%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $85.87 | +17.62% | 3 | Sep 12, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $18 | $8.07 | +123.19% | 1 | Aug 21, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $24.39 | +6.60% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $24.50 | +75.51% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $9.09 | +164.03% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $31.86 | -30.95% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $6.80 | -11.76% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $75.20 | +40.96% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $11.38 | +207.56% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.08 | +526.51% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.45 | +22.45% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $2.42 | +1,552.89% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.26 | +931.75% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $40.22 | -25.41% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $23.40 | -1.71% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $58.98 | -15.23% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $17.47 | +707.10% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.65 | +93.55% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $24.12 | -8.79% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.85 | +44.33% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.07 | +13.15% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $27.19 | +69.21% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.78 | +151.80% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $14.84 | +270.74% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $143.14 | -67.86% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $104.05 | -52.91% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $960.10 | -61.46% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $79.30 | -60.91% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $79.87 | -4.85% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $104.52 | +74.13% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $97.26 | +10.01% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $136.25 | -30.28% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $18.40 | -2.17% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $146.96 | -21.07% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $99.75 | -61.90% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $128.88 | -82.93% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.41 | -48.08% | 9 | Apr 29, 2020 |
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $85.87
Upside: +17.62%
Trevi Therapeutics
Aug 21, 2025
Initiates: Overweight
Price Target: $18
Current: $8.07
Upside: +123.19%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $24.39
Upside: +6.60%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $24.50
Upside: +75.51%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $9.09
Upside: +164.03%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $31.86
Upside: -30.95%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $6.80
Upside: -11.76%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $75.20
Upside: +40.96%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $11.38
Upside: +207.56%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.08
Upside: +526.51%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.45
Upside: +22.45%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $2.42
Upside: +1,552.89%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.26
Upside: +931.75%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $40.22
Upside: -25.41%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $23.40
Upside: -1.71%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $58.98
Upside: -15.23%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $17.47
Upside: +707.10%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.65
Upside: +93.55%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $24.12
Upside: -8.79%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.85
Upside: +44.33%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.07
Upside: +13.15%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $27.19
Upside: +69.21%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.78
Upside: +151.80%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $14.84
Upside: +270.74%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $143.14
Upside: -67.86%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $104.05
Upside: -52.91%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $960.10
Upside: -61.46%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $79.30
Upside: -60.91%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $79.87
Upside: -4.85%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $104.52
Upside: +74.13%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $97.26
Upside: +10.01%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $136.25
Upside: -30.28%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $18.40
Upside: -2.17%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $146.96
Upside: -21.07%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $99.75
Upside: -61.90%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $128.88
Upside: -82.93%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.41
Upside: -48.08%